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Temporary changes in cellular antigenicity reflecting an adaptational altera- 
tion were originally observed in leukemic cells  and termed antigenic modula- 
tion (1, 2). Subsequently, transitory (3-6) or permanent (7-8) loss of antigenic 
expression has been described in other systems and correlated with an increased 
capacity for allogeneic transplantation (9-11). 
Such changes of cellular antigenicity represent a  major modality by which 
growing tuamors (12) and transplanted tissues (4) escape immunologic annihila- 
tion. It is therefore of great interest to study the mechanisms of antigenic varia- 
tion and the correlation  between  transplantability and expression  of various 
antigens. We have previously reported observations on Gross virus-induced rat 
lymphomas that  lost virus replication and  Gross murine  leukemia  virus  (G- 
MuLV) l antigenic expression during serial transplantation and  recovered both 
when explanted in vitro (5). 
In  the present  work,  attempts  were made  to establish  a  system in  which 
changes of antigenicity can be deliberately induced in order to facilitate  the 
study of their mechanics. This was achieved by injection of deaggregated anti- 
gen into newborn rats, resulting in a long-lasting state of partial  immunologic 
tolerance to Gross virus-induced lymphoma cells.  Subsequent  to  their  trans- 
plantation in partially tolerant rats the lymphoma cells showed loss  of  mem- 
brane G-MuLV antigens with maintenance of cytoplasmic antigenicity.  This 
antigenic disjunction made the cells serially transplantable in  nonconditioned 
adult hosts, which further resulted in the loss of internal specific antigens. 
Materials and Methods 
Induction  of Lymphoma.--1-  to  4-day  old  (W/Fu)  rats were  given  one  intraperitoneal 
(i.p.)  injection of 0.1-ml stock  rat-adapted  Gross lymphoma virus  (GLV)  diluted  1:10 in 
medium 199.  As previously reported  (13)  an incidence of nearly 100% induction of thymic 
lymphoma was obtained within an average latency period of 73 days. 
* This work was supported by grant CA 10273-06  from the National Cancer Institute. 
i Abbreviations  used in this paper:  GLV, Gross lymphoma virus; G-MuLV antigens, Gross 
routine leukemia virus antigens; PBS, phosphate-buffered saline; RaLV, rat leukemia virus. 
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Induction of Partial Immunologic Tolerance.--GLV-induced  thymic lymphomas were finely 
minced and a  20% suspension in phosphate-buffered saline (PBS) was prepared. The latter 
was homogenized at 4°C  in a  Waring blender (Waring Products Div.,  Dynamics Corp.  of 
America, New Hartford, Conn.) and subsequently sonifled for 60 s at 0°C in a  100 W  ultra- 
sonic  MSE  disintegrator  (MSE  Inc., Westlake,  Ohio)  to  solubilize  the  antigenic  compo- 
nents. This was followed by  one  10,000 g centrifugation for  10 min at 4°C. The supernate 
was spun at  100,000  g for 1  h  at 4°C and the resulting supernate passed through a  10 nm 
pore size millipore filter. 1- to  3-day old W/Fu rats were injected i.p. with 0.1 ml of this prep- 
aration. 
Transplantation.--75-  to  120-day old W/Fu rats were grafted with GLV-induced  thymic 
lymphomas or subsequent generations of transplanted lymphomas. The grafts consisted  of 
3 mm  3 of tumor tissue introduced subcutaneously by a cutdown in the skin of the left side of 
the thorax. Assessment of tumor acceptance was made after 30 days. 
Indirect Immunofluorescence.-- 
Membrane antigens:  to  determine  the  presence  of  G-MuLV  antigens  on  the  cellular 
membranes the method of M611er (14) was used. The  tumors to be assayed were minced and 
the cells suspended in 199 medium. 0.1 ml of this suspension containing 2 X  106 cells was added 
to 0.1 ml anti-G-MuLV serum and incubated for 30 rain at 37°C. Subsequently, the ceils were 
washed twice in 199 medium and incubated with 0.1 ml of 1 : 10 fluorescein-conjugated goat 
antirat globulin (Hyland Laboratories, Costa Mesa,  Calif.) for 1 h at 37°C.  After three wash- 
ings with 199 medium the cells were mounted  in 500/0 glycerol in  PBS,  coversliped,  and ex- 
amined under a  Leitz fluorescence  microscope equipped with a  BG 12 exciter  filter,  K  530 
barrier filters, and a  high pressure HBO 200 W  mercury  bulb (E. Leitz, Rockleigh, N. J.). 
The G-MuLV antisera used in all immunologic assays were raised in (W/Fu X  BN)F1 hybrid 
rats grafted with GLV-induced W/Fu  lymphomas, according to the method of Geering et al. 
(15). 
Cytoplasmic antigens:  To determine the presence of G-MuLV intracytoplasmic antigens, 
an indirect immunofluorescence technique was used. As previously described (5, 10) the tissues 
were minced and the cells suspended in 199 medium at 1 X  106 cells/ml and placed on micro- 
scopic slides which were incubated overnight in a  CO2 gassed incubator at 37°C. The cells 
were then washed in Hanks' solution, dried 1-2 h at 37°C, fixed for 10 rain in acetone at room 
temperature,  and  used  immediately  or  stored  at--20°C.  Drops  of  anti-G-MuLV  serum 
at various dilutions were placed over the ceils and the cells incubated at 37°C for 1 h,  then 
washed twice with PBS at pH  7.2  and twice in distilled  water. The slides were air  dried, 
covered with fluorescein-labeled goat antirat globulin and incubated for  1 h  at 37°C.  Sub- 
sequently, they were washed twice in PBS and once in distilled water. The slides were counter- 
stained with 0.06% Evans' blue stain for 1 rain at 37°C, washed twice in distilled water,  and 
dried. They were mounted in 500/o glycerol in PBS, coversliped, and examined under a  Leitz 
fluorescence microscope as described (E. Leitz). 
Gel Microimmunodi~usion.--A  modification of the Ouchterlony double-diffusion technique 
(16)  previously described  (10)  was used for producing immune precipitates in gel.  Soluble 
antigen fractions of tumor tissue were prepared by ultrasonic disruption at 0°C followed by 
centrifugal clarification at  70,000  g  for  2  h.  The  precipitating anti-G-MuLV homologous 
antisera were produced as previously described. The double-diffusion tests were performed in 
IDF cells  (Cordis Laboratories Miami, Fla.). 
A ntibody Cytotoxicity.--An  established rat thymic culture that permanently replicates the 
GLV (17) was used as the source for target cells (G cells). The cells were suspended in 1 ml  of 
Puck's medium with 15% fetal bovine serum, assessed for viability with the trypan blue dye 
test, and adjusted to 1 X  106 cells/ml. 1 ml of the cell suspension was incubated with 200- 
300 #Ci of SlCr  (sodium chromate specific activity 10/zCi/#g Cr, at a  concentration of 10 
#Ci/ml; The Radiochemical Centre, Amersham, England) at 37°C for 30-40 rain as described 
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and adjusted to 1 X  106 cells/ml, then 0.1 ml was added to 0.1 ml of serial twofold dilutions of 
anti G-MuLV rat antiserum inactivated at 56°C for 30 min. After incubation for 30 min at 
37°C,  0.1 ml of noncytotoxic fresh rabbit serum was added as the source of complement and 
the incubation continued for another 30 min. 2 ml of cold Eagle's medium were added to each 
tube, the cells were sedimented by centrifugation at 500 g for 10 rain, and then 0.1 ml of the 
supernatant  fluid of each tube was counted for released radioactivity in a  Nuclear-Chicago 
automatic  gamma  scintillation  counter  (Nuclear-Chicago  Corp.,  Des  Haines,  Ill.).  The 
release of SlCr in counts per minute was considered as the index of cell sensitivity to a known 
cytotoxic and anti-G-MuLV  antiserum.  The spontaneous  release of SlCr in the presence of 
complement alone was considered as  the control baseline. The maximum  51Cr release was 
obtained by freezing and thawing the cells four times. 
Complement Fixation.--The  tests were conducted  in the laboratory of Dr.  R.  J.  Hueb- 
net (National Cancer Institute)  according to a  technique previously described  (19). 
Induction of Focus-Formlng RNA  Virus.--Investigation  for the presence of rat  leukemia 
virus  (RaLV)  was  made  in  the laboratory  of Dr.  R.  J.  Huebner.  The  technique  of focus 
formation induction in cloned nonproductive rat cell lines after treatment with 5t-bromodeoxy  - 
uridine, as previously described (20), was used. 
Electron Microscopy.--1-mm cubes of tumor tissue were fixed in 3% gluteraldehyde solu- 
tion in 0.075  M  sodium cacodylate buffer,  pH 7.2,  for 24 h  at 4°C as previously described 
(13).  Postfixation was carried out in 1% osmium tetroxide in veronal acetate buffer, pH 7.2, 
for 2 h. After dehydration in a series  of graded ethanol solutions, tissue fragments were em- 
bedded in Epon. Sections were cut on an LKB ultrotome (LKB Instruments, Inc., Rockville, 
Md.) and thin sections were double stained with uranylacetate. The grids were examined in a 
Siemens  Elmiskop  101  (Siemens  Corp.,  Medical Industrial  Div., Iselin, N.  J.)  and  photo- 
graphed  at an initial magnification of 6,000-20,000  diameters. 
RESULTS 
Rats  injected  at  birth  with  soluble  antigen  and  matched  normal  controls 
were grafted subcutaneously at age 75-120 days with GLV-induced lymphomas. 
In three separate experiments, a  total of l0 recipients conditioned at birth with 
different pools of soluble antigens were grafted with GLV-induced lymphomas. 
Nine accepted  the grafts which grew progressively and killed the  recipients in 
contrast  to all of 16 normal  controls which rejected the same  transplants.  The 
growing tumors were then grafted into normal-nonconditioned adult W/Fu  rats 
and  the grafts  took in  17 of 23, while none of 12  grafts of primary ]ymphomas 
used as controls took in similar normal  recipients  (Table I). Subsequently,  the 
tumors  originally grafted in neonata]ly  conditioned rats  became serially trans- 
plantable in nonconditioned recipients. In eight successive tumor generations a 
total of  146  tumors  were  grafted  in  normal  adult  recipients  and  125  were  ac- 
cepted. The percentage of successful takes generally increased with the number 
of  the  tumor  generation.  However,  qualities  intrinsic  to  the  original  tumor 
seemed to be of even greater importance for future transplantability,  since some 
lines of tumors resulted in less than  100 %  takes while others showed total takes 
in  all grafts  throughout  their tumor generations.  Thus,  in the first experiment 
in which two lines of transplantable  tumors originating in two-conditioned rats 
were followed, the rate of takes was  19/27  (70.3 %)  in the first line and  84/84 H.  L.  IOACHIM~  S.  E.  KELLER,  B.  H.  DORSETT,  A.  PEARSE  1385 
TABLE I 
Correlation of G-MuLV  Antigens  with  Transplantability  of Lymphoma  Cells 
Recipient 
Normal control 
Zonditioned at birth 
Normal--tr. gener. 1 
Normal--tr. gener. 2 
Normal--tr. gener. 3 
~qormal--tr.  gener. 4 
~ormal--tr. gener. 5 
~ormal--tr. gener. 6 
~ormal--tr. gener. 7 
Origin 
GLV-lymphoma 
GLV-lymphoma 
Lymphoma--L1 
Lymphoma--L 
Lymphoma--L3 
Lymphoma--L4 
Lymphoma--L5 
Lymphoma--L6 
Lymphoma--L7 
Transplant 
Antigenicity 
MF§  CFII  ID¶  No.** 
+  +  +  16 
+  +  +  10 
-  +  +  7 
=  +  ± 
--  +-  -+ 
-+_+2  6 
-  +  +-  1~ 
-  _+_+  0 
Results 
L/T*  %  G* 
0/16  0.0  -- 
9/10  90.0  L1 
17/23  73.9  L2 
33/39  84.6  L3 
32/38  84.2  L4 
22/24  91.7  L5 
13/13  100  L6 
9/9  100  L7 
6/6  100  L8 
* L, lymphoma takes; T, total lymphoma transplanted. 
G, successful grafts used for subsequent transplantation. 
§ MF, membrane immunofluorescence. 
H CF, cytoplasmic immunofluorescence. 
¶ ID, gel microimmunodiffusion. 
** number of transplants assayed. Example: recipients in transplant generation 2 were 
grafted with lymphoma L~ which was MF--, CF+, ID +  in five animals tested and MF--, 
CF--, ID-- in nine animals tested. 33 of 39 grafts took (84.6%).  These tumors designated 
L3 were  subsequently grafted in recipients ti:. gener.  3.  Two  of them were  MF--, CF+, 
ID+ and nine were MF--, CF--, ID-- etc. 
(100%)  in the second.  In the second experiment the rates of takes were  6/16 
(37.5 %) in one tumor line and 16/19  (84.2 %) in another. 
To correlate tumor transplantability with antigenic experession, all graft re- 
cipients were  examined  for  the  presence  and  amount  of  anti-G-MuLV  anti- 
bodies and all the tumors were studied for cellular antigenicity using five differ- 
ent assays. The lymphoma cells originally grafted in neonatally conditioned rats 
showed  numerous  GLV  particles under  the  electron microscope  (Fig.  1)  and 
were strongly positive in indirect immunofluorescence for both membrane (Fig. 
2) and cytoplasmic (Fig. 3)  G-MuLV antigens. Antigens of  these  cells also re- 
acted  positively with  anti-G-MuLV  antiserum  in  gel  microimmunodiffusion 
tests, antibody cytotoxicity assays, and complement fixation tests. 
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FIo.  1.  GLV-induced thymic lymphoma cell showing numerous C-type virus particles at 
the plasma membrane and in the intercellular space. Budding virus particle at arrow. X  60,000 
now tested in indirect immunofluorescence it was found that membrane and 
cytoplasmic G-MuLV antigenicity had dissociated, and that the cells were still 
displaying positive cytoplasmic fluorescence while the membrane fluorescence 
was no longer present. As the tumors were further transplanted it appeared that 
the membrane antigenicity had been permanently lost. The cytoplasmic fluores- 
cence, indicating G-MuLV antigenicity, persisted in the serially transplantable 
tumors for two to three more generations and similarly disappeared thereafter. 
At  one point in  every experiment, after a  number of transplant  generations 
(3-6) all the transplanted tumors became negative for both membrane and cyto- 
plasmic antigenicity in indirect immunofluorescence. The loss  of antigenic ex- 
pression in the transplanted  tumor cells  was confirmed by gel  microimmuno- 
diffusion, complement fixation, and antibody cytotoxicity tests. All these assays 
were consistently negative and no indication of persistent G-MuLV antigenicity 
was detected. Attempts to explant these cells in tissue cultures were generally 
unsuccessful and a few cultures which were grown for intervals of up to 90 days 
did not show recovery of cellular antigens. H.  L.  IOACHIM~  S.  E.  KELLER~  B.  H.  DORSET%  A.  PEARSE  1387 
FIG. 2. GLV-induced  thymic lymphoma cells showing positive membrane reaction in in- 
direct immunofluorescence after staining with anti-G-MuLV antiserum. X 2,100 
The  loss of  G-MuLV antigenic expression occurred progressively:  that  of 
membrane antigens in the first transplant generation and that of cytoplasmic 
antigens in an increasingly greater number of transplanted tumors in later gen- 
erations. The acceptance of tumor grafts consistently correlated with antigenic 
expression. Tumors with positive membrane antigenicity such as primary GLV- 
induced lymphomas were rejected in close to  100% of the recipients, tumors 
with  absence of both membrane and  cytoplasmic  antigenic  expression  were 
accepted in 100 % of the recipients, and tumors with antigenic disjunction, mem- 
brane negative and cytoplasmic positive, were accepted in 37.5-84.2 % of the 
recipients (Table II). 
Sera of normal-nonconditioned rats who had accepted transplantable tumors 
were assayed for the presence of anti-G-MuLV antibodies in parallel with rats 
that had rejected primary GLV-induced lymphomas. It was found that normal- 
nonconditioned rats bearing the transplantable  tumors that  showed negative 
membrane fluorescence and positive cytoplasmic fluorescence, had  sera  with 
high anti-G-MuLV antibody titers (Table III). Such titers displayed a range of 
1 : 8-1 : 1,024 with a mean reciprocal titer of 80 in indirect immunofluorescence, 
which was considerably higher than rats that rejected tumors with both positive 1388  IMMUNOLOGIC  TOLERANCE  AND  LOSS OF  ANTIGENICITY 
membrane and cytoplasmic antigenicity. Even more surprising, rats grafted with 
tumors  showing,  for the  first  time in  their serial  transplantation,  absence  of 
both membrane and cytoplasmic antigenicity still showed high anti-G-MuLV 
antibody titers with a mean reciprocal titer of 340. However, after two to three 
consecutive  generations  of negative  membrane  and  cytoplasmic  antigenicity, 
serum anti-G-MuLV antibody titers declined to ranges of 1:4-1:64 with a mean 
reciprocal titer of 20. The high titers of antibodies recorded in  immunofluores- 
cence were consistently confirmed by parallel microimmunodiffusion, antibody 
FIC.  3.  GLV-induced  thymic  lymphoma  cells  showing  positive  cytoplasmic  reaction  in 
indirect immunofluorescence after staining with anti-G-MuLV antiserum X  2,000 
TABLE  II 
Correlation  of  Transplantability  with  Membrane  and  Cytoplasmic  Indirect 
Immunofluorescence Test 
Immtmofluorescence  Transplantability 
L/T*  % 
membrane  +  cytoplasm  +  1/28  3.5 
membrane  --  cytoplasm  +  36/55  65 
membrane  -  cytoplasm  --  89/91  98 
* L, lymphoma takes; T, total lymphoma transplanted. Ii.  L.  IOACHIM, S.  E.  KELLER, B.  H.  DORSETT, A.  PEARSE  1389 
cytotoxicity, and complement fixation tests. Assays for the identification of a 
possible RaLV by the focus-forming assay (20) were negative. 
DISCUSSION 
The normal immunologic response of an animal to a  specific antigen can be 
altered under a  variety of conditions. A large number  of reports  dealing  with 
this subject indicate its interest for both tumor and transplantation biology. 
When antigen is administered in early life, before the acquisition of immuno- 
competence, the animal is rendered tolerant and will not react to that specific 
antigen when exposed to it later in life (21). When antigen in high dosage is given 
to an  adult  animal,  a  state of partial  immunologic paralysis  may ensue  (22). 
Finally, when animals receiving a  tumor homograft are preinjected with killed 
tumor tissue the growth of the tumor is markedly enhanced (23, 24). This effect 
can be passively transferred to new hosts with serum (23) or immunoglobulins 
(25)  of pretreated  recipients.  The mechanism of tumor enhancement  has long 
been debated and alternately attributed to either (a) blocking by antibodies of 
the development of cellular immunity in the regional lymph nodes (24, 26, 27), 
or to (b) some unknown physiological alteration in the tumor induced by its con- 
tact with the specific antibodies (23). 
TABLE III 
Correlation  of G-MuL V Antigens, Transplantability, and A nti-G-MuL V Sera Titers in Indirect 
Immunofluorescence Tests 
Transplant 
Recipient  Antigenicity  Sera (mean)  ~ 
Origin  Takes* 
MF§  CFII 
Normal control  GLV-lymphoma  +  +  0/11  43.1 
Conditioned at birth  GLV-lymphoma  +  +  9/10  64.0 
Normal--tr. gener. 1  Lymphoma--L1  --  +--  7/72/2  587.2'  4/457.03 
+  4/6  258.6 
Normal--tr. gener. 2  Lymphoma--L2  ----  -4-  21/21  250.6/359.5 
Normal--tr. gener. 3  Lymphoma--La  ----  +--  23/234/8  181.2/152.  555.  2 
Normal--tr. gener. 4  Lymphoma--L4  --  -b_  16/166/8  48.4/49.  050.  6 
Normal--tr. gener. 5  Lymphoma--Ls  --  ----  11/112/2  36.0/39.  064.  0 
-  -  1/1  o.o 
Normal--tr. gener. 6  Lymphoma--Ls  --  8/8  50.0/40.0 
* Takes, lymphoma takes/total lymphoma transplanted. 
:~ Means, mean reciprocal titers. 
§ MF, membrane immunofluorescence. 
I[ CF, cytoplasmic immunofluorescence. 1390  IMMUNOLOGIC  TOLERANCE  AND  LOSS  OF  ANTIGENICIT¥ 
The physical form in which antigen is administered was shown to be of es- 
sential importance (28-30). Living cells as well as antigens in a particulate form 
are immunogenic and able to sensitize adult immunocompetent animals. How- 
ever, similar recipients do not react to deaggregated antigens which induce a 
state of complete and prolonged immunologic unresponsiveness to subsequent 
challenge of the aggregated antigen (28-31). 
In the present work, newborn rats were injected with deaggregated G-MuLV 
antigen and challenged later in life with grafts of lymphoma cells expressing the 
full complement of G-MuLV antigens. The cells grew progressively killing the 
host in contrast to their rejection which occurred consistently in normal-non- 
conditioned control animals. Similar results were obtained by Kobayashi et al. 
(32), who reported that rats injected at birth with live Friend, Gross, or Rauscher 
virus were tolerant to transplants of each particular tumor. 
Before attempting to classify this situation into one of the categories pre- 
viously mentioned,  an  additional  feature  must  be  taken  into  account.  The 
grafted lymphoma cells able to grow in the apparently unresponsive-conditioned 
hosts incurred the loss of membrane antigens, which was readily detectable by 
immunofluorescence tests. If we assume that these changes occurred under im- 
mune pressures from the host, it appears that the conditioned rats although un- 
able to reject the grafted lymphoma cells did respond in a way that induced the 
loss of cellular surface antigens. 
This situation is therefore unlike both immunologic tolerance (28)  and im- 
munologic paralysis (22) where the lack of any responses are assumed. The ab- 
sence of a complete immunologic tolerance as classically described was also re- 
ported by Oldstone et al.  (33)  to occur in AKR mice, which despite the per- 
sistence throughout their life of vertically acquired Gross virus are still able  to 
form specific anti-G-MuLV antibodies. There are also difficulties in explaining 
the failure of graft rejection in the conditioned rats by immunologic enhance- 
ment when this is conceived as  a  blockade of  antigenic  sites  by specific an- 
tibodies  raised  by the  host  (24,  26,  34).  As  pointed  out  by  Medawar  (28), 
immunologic enhancement being mediated through antibody depends on the 
success of immunization and not on its failure. However, enhancement in the 
interpretation of Kaliss (23)  represents some "physiological" alteration in the 
tumor, induced by its contact with antiserum which insures its survival despite 
the hostile responses of the host. An alternative to this concept, possibly appli- 
cable to the present situation, may be that the immune response of the host 
forces a clonal selection among the grafted tumor cells. 
We have selected the term immunologic tolerance and qualified it as partial 
and specific to describe the immune status of rats injected at birth with soluble 
G-MuLV antigen. These animals are tolerant to progressive tumor growth, ho, -- 
ever, the tolerance is only partial since they are still able to induce permane~ 
antigenic changes in the grafted lymphomas. The changes result in the emer- 
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loss of specific surface antigens, to survive in the hostile environment of an im- 
munocompetent host. In further transplant generations, in normal-noncondi- 
tioned immunocompetent recipients,  the lymphoma cells  protected  by their 
lack of surface antigens grew progressively, however, further antigenic changes 
occurred, this time expressed by the loss of the internal G-MuLV antigens. 
This was a  finding of particular interest, not previously reported in other 
systems, i.e., that the loss of antigens occurred progressively in the course of 
serial transplantation and resulted in a temporary disjunction between surface 
and internal antigenic components. Concerning other cases of antigenic disjunc- 
tion an example may be provided by the expressions of RNA viral envelope, 
group specific antigens, and oncogene which appear independently (35).  How- 
ever, even in this case they all are quite aslikely to be expressed at the same time3 
In the present experiments antigenic losses were paralleled by progressive in- 
crease in  transplantation takes, which rose from 3.5 %  in cells  with positive 
membrane and cytoplasmic antigens, to 65 % in cells with dissociation of anti- 
genic expression, and  to 98 %  in cells  with total absence  of antigenic deter- 
minants. It is not clear at the present time if these antigenic deletions have 
occurred by repression of antigen synthesis or by immune selection of lymphoma 
cells devoid of antigenic expression. Similarly, we do not know if these antigenic 
losses  are still reversible as in our earlier experiments (5)  where antigenic ex- 
pression returned after explantation in vitro. 
The unusually high titers of anti-G-MuLV antibodies detected in sera of rats 
bearing transplants of membrane-negative lymphoma cells  were rather unex- 
pected. Even more so were sera titers that continued to rise  above normal in 
animals with both membrane and cytoplasmic G-MuLV-negative grafts. This 
was in sharp contrast with much lower anti-G-MuLV antibody titers  in rats 
bearing lymphoma transplants showing the presence of both membrane and 
cytoplasmic antigens which were regularly rejected. A possible explanation for 
this apparent inconsistency may be the fact that lymphoma grafts lacking sur- 
face antigenic determinants grew to huge proportions and were carried for long 
intervals, in contrast to lymphoma grafts expressing G-MuLV  antigens which 
were readily rejected. If very small, perhaps undetectable, amounts of antigens 
were still present on the former cells then the large number of cells and  long 
duration of grafts may be  accountable for  the  high  rise  in  antibody titers. 
Another possible explanation would be that the antibodies were in response to 
different cell surface antigens (36) associated with GLV or perhaps with RaLV 
membrane antigens,  ~ although assays for the identification of RaLV have re- 
mained negative. 
Notwithstanding, in later transplant generations, when both surface and in- 
ternal antigens had already been absent for one to three passages, the antibody 
titers of tumor-bearing animals consistently fell to baseline levels. There are 
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presently numerous transplantable tumors available in our laboratories. These 
tumors which have been around for many years and are the result of numerous 
successive transplantations have two features in common: lack of any viral anti- 
genic expression and a high rate of transplantability. 
It seems reasonable to suggest, in light of the experiments reported here, that 
most of these tumors were originally virus induced and initially displayed viral- 
associated antigens. Attempts to transplant such tumors must have failed in all 
but those recipients which displayed either partial tolerance acquired at  birth 
or temporary immunologic unresponsiveness induced by various agents during 
adult life. After the first transplant was thus established, immunological selec- 
tion of antigen-negative clones of cells or immunological repression of antigen 
production made subsequently possible the successful serial grafting of these 
tumors. This system, together with recent evidence from work  with  Burkitt 
lymphoma cells in tissue cultures (37) and thymusless mice (6) may suggest that 
human tumor cells have undergone a similar antigenic evolution. 
SUMMARY 
Gross virus-induced lymphoma cells express strong virus-associated  (Gross 
murine leukemia virus [G-MuLV]) antigens and are consistently rejected when 
grafted in normal adult syngeneic rats. By contrast, similar grafts are tolerated 
and allowed to grow progressively by rats that have been injected at birth with 
deaggregated G-MuLV antigens. However, the tolerance induced by this pro- 
cedure is only partial as the grafted lymphoma cells lose their G-MuLV mem- 
brane  antigens.  These cells showing  an  antigenic disjunction,  with  negative 
membrane  and  positive  cytoplasmic  G-MuLV  antigenic  expression,  become 
transplantable in normal-nonconditioned adult recipients. By further grafting, 
the  expression  of  cytoplasmic G-MuLV  antigens  is  similarly  lost  while  the 
lymphoma cells substantially increase their transplantability, rate of growth, 
and capacity for metastasis. 
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